EUVIMEDEUVIMED entdecken
Open Access

Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co‐Infection in Senegal

Bruce Shinga Wembulua iD, Fredéric Le Gal, Ousseynou Ndiaye, Melissa Sandrine Pandi, Messan Kodzo Akotia, Aboubakar Sidick Badiane, Poussyina Hamouda, Judicaël Tine, Kiné Ndiaye, Charles Béguelin iD, Ndeye Fatou Ngom, Gilles Wandeler iD und 3 weitere

Liver International · 2025-03 · 45 (3)

DOI: 10.1111/liv.70026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 19.02.2025. Verfasst von Bruce Shinga Wembulua und 14 weiteren Autor:innen. Beteiligte Einrichtung: Service de Maladies Infectieuses et Tropicales, Fann University Hospital, Dakar, Senegal. Hauptthemen laut MEDLINE: Coinfection, Liver Cirrhosis, Hepatitis D, HIV Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Institut National Du Cancer, Swiss Cancer Research Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The prevalence of hepatitis delta virus (HDV) infection among persons living with hepatitis B virus (HBV) and its impact on liver‐related complications in West Africa are ill‐defined. Wetested a large urban HBV cohort in Senegal for the presence of HDV/HBV co‐infection and evaluated its association with liver fibrosis.

Methods

We included persons with positive hepatitis B surface antigen (HBsAg) enrolled in the SEN‐B cohort since 2019. Anti‐HDV antibodies (HDVAb) were tested using the Anti‐HD Diasorin LiaisonXL test, HDV RNA was measured with RT‐qPCR and genotyping was determined through sequencing. We used multivariable logistic regression to evaluate the association between HDVAb positivity and liver fibrosis, defined as a liver stiffness measurement > 7.0 kPa.

Results

We analysed 914 individuals with a median age of 32 years (interquartile range [IQR] 26–41), of whom 487 (53.3%) were men and 117 (12.8%) had HIV co‐infection. Thirteen participants (1.4%, 95% CI 0.8–2.4) had a positive HDVAb test, of whom 8/13 (61.5%) showed detectable HDV RNA. HDV genotype 5 was found in 75.0% of cases. In multivariable analyses, HDVAb positivity (aOR 11.7, 95% CI 3.1–45.7), male sex (aOR 5.4, 95% CI 3.1–10.3), ALT > 40 IU/L (aOR 4.4, 95% CI 2.4–8.2) and HBeAg positivity (aOR 4.6, 95% CI 1.8–11.9) were independently associated with liver fibrosis.

Conclusion

The prevalence of HDV infection was low in persons living with HBV in Dakar, but those affected had a very high risk of presenting with liver cirrhosis. Efforts to improve HDV screening and management are urgently needed in Senegal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoinfectionLiver CirrhosisHepatitis DHIV InfectionsHepatitis BHumansMaleSenegalFemaleAdultHepatitis Delta VirusPrevalenceHepatitis AntibodiesHepatitis B Surface AntigensLogistic ModelsRNA, ViralMiddle AgedHepatitis B virus

Stichwörter der Autor:innen

Senegalhepatitis Bhepatitis Dliver fibrosisprevalence

Substanzen

Hepatitis AntibodiesHepatitis B Surface AntigensRNA, Viral

Autor:innen und Institutionen

  • Service de Maladies Infectieuses et Tropicales, Fann University Hospital, Dakar, Senegal.
  • Centre National de Référence des Hépatites Virales B, C et Delta, Laboratoire de Microbiologie clinique, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris Cité, Bobigny, France.
  • Centre Régional de Recherche et Formation Clinique à la Prise en Charge de Fann, Fann University Hospital, Dakar, Senegal.
  • Doctoral School of Life Sciences, Health, and Environment, Cheikh Anta Diop University of Dakar, Dakar, Senegal.
  • Centre de Traitement Ambulatoire de Fann, Fann University Hospital, Dakar, Senegal.
  • Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Bruce Shinga Wembulua, Charles Béguelin, Gilles Wandeler, Adrià Ramírez Mena

Förderung

  • Institut National Du Cancer
  • Swiss Cancer Research Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Wembulua, B. S., Le Gal, F., Ndiaye, O., Pandi, M. S., Akotia, M. K., Badiane, A. S., Hamouda, P., Tine, J., Ndiaye, K., Béguelin, C., Ngom, N. F., Wandeler, G., Seydi, M., Mena, A. R., & SEN‐B (2025). Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co‐Infection in Senegal. Liver International, 45(3). https://doi.org/10.1111/liv.70026

Vancouver

Wembulua BS, Le Gal F, Ndiaye O, Pandi MS, Akotia MK, Badiane AS, et al. Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co‐Infection in Senegal. Liver International. 2025;45(3). doi:10.1111/liv.70026

BibTeX
@article{Wembulua2025,
  author = {Wembulua, Bruce Shinga and Le Gal, Fredéric and Ndiaye, Ousseynou and Pandi, Melissa Sandrine and Akotia, Messan Kodzo and Badiane, Aboubakar Sidick and Hamouda, Poussyina and Tine, Judicaël and Ndiaye, Kiné and Béguelin, Charles and Ngom, Ndeye Fatou and Wandeler, Gilles and Seydi, Moussa and Mena, Adrià Ramírez and SEN‐B, SEN‐B},
  title = {Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co‐Infection in Senegal},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1111/liv.70026}
}
Kostenlos starten →